Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species

A survey of five Nocardia spp. with respect to susceptibility towards three macrolides (erythromycin, rokitamycin, and midecamycin) showed that the Nocardia spp. have different susceptibility profiles. Most of the resistance was due to the inactivation of the macrolides by phosphorylation, glycosylation, reduction, deacylation, or a combination thereof.

[1]  S. Iwasaki,et al.  Inactivated products of rifampicin by pathogenic Nocardia spp.: structures of glycosylated and phosphorylated metabolites of rifampicin and 3-formylrifamycin SV. , 1993, The Journal of antibiotics.

[2]  P. Doherty,et al.  Microbial conversion of avermectins by Saccharopolyspora erythraea: glycosylation at C-4' and C-4'' , 1993, Antimicrobial Agents and Chemotherapy.

[3]  S. Iwasaki,et al.  Inactivation of rifampin by Nocardia brasiliensis , 1993, Antimicrobial Agents and Chemotherapy.

[4]  M. Miyaji,et al.  In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp. , 1992, The Journal of antimicrobial chemotherapy.

[5]  E. Cundliffe,et al.  Cloning and characterization of two genes from Streptomyces lividans that confer inducible resistance to lincomycin and macrolide antibiotics. , 1991, Gene.

[6]  R. Leclercq,et al.  Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria , 1991, Antimicrobial Agents and Chemotherapy.

[7]  T. Kudo,et al.  Inactivation of Kanamycin A by Phosphorylation in Pathogenic Nocardia , 1991, Microbiology and immunology.

[8]  E. Eady,et al.  Multiple mechanisms of erythromycin resistance. , 1990, The Journal of antimicrobial chemotherapy.

[9]  M. Kuo,et al.  Microbial glycosylation of erythromycin A , 1989, Antimicrobial Agents and Chemotherapy.

[10]  K. Yazawa,et al.  In vitro susceptibility of Nocardia spp. to a new fluoroquinolone, tosufloxacin (T-3262) , 1989, Antimicrobial Agents and Chemotherapy.

[11]  K O'Hara,et al.  Purification and characterization of macrolide 2'-phosphotransferase from a strain of Escherichia coli that is highly resistant to erythromycin , 1989, Antimicrobial Agents and Chemotherapy.

[12]  R. A. Johnson,et al.  Microbial O-phosphorylation of macrolide antibiotics. , 1989, The Journal of antibiotics.

[13]  H. Seto,et al.  Particular utility of the HMBC technique to polypropionate derived metabolites as exemplified by erythromycin A. , 1988, The Journal of antibiotics.

[14]  J. Cialdella,et al.  Enzymatic phosphorylation of macrolide antibiotics. , 1987, The Journal of antibiotics.

[15]  S. Inouye,et al.  Studies on antibiotic SF-837, a new antibiotic. IV. Structures of antibiotics SF-837 A 2 , A 3 and A 4 . , 1971, The Journal of antibiotics.

[16]  T. Shomura,et al.  Studies on antibiotic SF-837, a new antibiotic. I. The producing microorganism and isolation and characterization of the antibiotic. , 1971, The Journal of antibiotics.

[17]  Y. Mikami.  Susceptibility patterns of pathogenic Nocardia to some selected antimicrobial agents and their usefulness in the identification work in a clinical laboratory. , 1989 .

[18]  J. Everett,et al.  An analysis of the 1H and 13C n.m.r. spectra of erythromycin a using two-dimensional methods , 1985 .

[19]  H. A. Whaley,et al.  MICROBIOLOGICAL TRANSFORMATIONS OF MACROLIDE ANTIBIOTICS. , 1963, Antimicrobial agents and chemotherapy.